SRNE : Summary for Sorrento Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.10-0.10 (-2.38%)
At close: 4:00PM EDT

4.20 0.00 (0.00%)
After hours: 4:00PM EDT

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4.20
Bid0.00 x
Ask7.25 x 100
Day's Range4.07 - 4.20
52 Week Range3.90 - 8.35
Avg. Volume177,328
Market Cap208.62M
PE Ratio (TTM)-2.55
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017
    Capital Cube12 hours ago

    Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017

    Categories: Yahoo Finance Get free summary analysis Sorrento Therapeutics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Sorrento Therapeutics, Inc. – Synergy Pharmaceuticals, Inc., Exelixis, Inc., Sucampo Pharmaceuticals, Inc. Class A and Karyopharm Therapeutics, Inc. (SGYP-US, EXEL-US, SCMP-US and KPTI-US) that have also reported for ... Read more (Read more...)

  • CNW Group5 days ago

    Sorrento and Wildcat Announce Resolution

    Sorrento and Wildcat Announce Resolution

  • PR Newswire5 days ago

    Sorrento and Wildcat Announce Resolution

    SAN DIEGO, March 20, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (SRNE) (the "Company" or "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Wildcat Capital Management LLC ("Wildcat"), whose clients currently are major holders of the outstanding common stock of Sorrento, today jointly announced that they have reached a mutual understanding and resolution with respect to Wildcat's claims seeking inspection of documents related to the Company's private placement agreements announced by the Company in April 2016 ("Inspection Demand Action") and Wildcat's derivative action against the Company and certain members of its Board of Directors filed in May 2016  ("Derivative Action").